title: Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials.
abstract: Etravirine is a recently approved nonnucleoside reverse transcriptase inhibitor. The ability of etravirine to limit the emergence of resistance to protease inhibitors, and specifically to darunavir, was investigated in the subset of treatment-experienced patients with virologic rebound in the phase III DUET trials. Of those experiencing rebound, fewer etravirine-treated than placebo-treated patients developed mutations associated with resistance to protease inhibitors in general and to darunavir in particular, and more patients in the etravirine than the placebo-group maintained baseline darunavir susceptibility at endpoint.
authors.affiliation: Tibotec BVBA, Mechelen, Belgium. mpeeter7@its.jnj.com
authors.forename: Monika
authors.initials: M
authors.lastname: Peeters
authors.forename: Johan
authors.initials: J
authors.lastname: Vingerhoets
authors.forename: Lotke
authors.initials: L
authors.lastname: Tambuyzer
authors.forename: Hilde
authors.initials: H
authors.lastname: Azijn
authors.forename: Andrew
authors.initials: A
authors.lastname: Hill
authors.forename: Sandra
authors.initials: S
authors.lastname: De Meyer
authors.forename: Gaston
authors.initials: G
authors.lastname: Picchio
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D024921:Drug Resistance, Multiple, Viral / Q000187:drug effects* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy* / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D009154:Mutation; D009570:Nitriles; D011724:Pyridazines / Q000494:pharmacology*; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*
chemical_list: D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; D018894:Reverse Transcriptase Inhibitors; C451734:etravirine